Our Science

Our Research

Through pioneering science and an unwavering commitment to patients, Alnylam has led the translation of the breakthrough discovery of RNA interference (RNAi) into an innovative class of medicines that is disrupting how disease is treated.

Our robust pipeline of investigational RNAi products is currently focused on diseases with high unmet medical need. Additionally, we will continue to follow the science, constantly exploring how our technology can help new patient populations.

For more information on the Alnylam Clinical Development Pipeline, visit here.

Clinical Trials

Innovative science is only part of the equation when it comes to developing new medicines. Clinical research relies on partnerships with Healthcare Professionals (HCPs) and patient advocates and, most importantly on the people who choose to participate in clinical trials.

We’re working to develop treatments for a broad range of rare and more common diseases using medicines based on RNA interference (RNAi). Our robust pipeline of investigational RNAi therapeutics is currently focused on several disease areas including transthyretin amyloidosis, rare diseases, cardiovascular diseases, metabolic diseases, neurological diseases and others.

For detailed information about our clinical trials, click here or visit www.clinicaltrials.gov to learn more.

If you have any questions about our clinical trials, please contact us:

Toll: +44 (0) 1628 878 592

Toll-free: 0800 141 2569 (also hidden caller ID)

Email: medinfo@alnylam.com